| Exome sequence analysis suggests that genetic burden contributes to phenotypic variability and complex neuropathy C Gonzaga-Jauregui, T Harel, T Gambin, M Kousi, LB Griffin, ... Cell reports 12 (7), 1169-1183, 2015 | 245 | 2015 |
| Motor protein mutations cause a new form of hereditary spastic paraplegia AC Oteyza, E Battaloğlu, L Ocek, T Lindig, J Reichbauer, AP Rebelo, ... Neurology 82 (22), 2007-2016, 2014 | 69 | 2014 |
| PLA2G6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia B Ozes, N Karagoz, R Schüle, A Rebelo, MJ Sobrido, F Harmuth, ... Clinical genetics 92 (5), 534-539, 2017 | 46 | 2017 |
| Unraveling the genetic landscape of autosomal recessive Charcot-Marie-Tooth neuropathies using a homozygosity mapping approach M Zimoń, E Battaloğlu, Y Parman, S Erdem, J Baets, E De Vriendt, ... neurogenetics 16, 33-42, 2015 | 46 | 2015 |
| Gene therapy to promote regeneration in Charcot-Marie-Tooth disease Z Sahenk, B Ozes Brain research 1727, 146533, 2020 | 36 | 2020 |
| Ultrasonographic findings in hereditary neuropathy with liability to pressure palsies AO Bayrak, IK Bayrak, E Battaloglu, B Ozes, O Yildiz, MK Onar Neurological research 37 (2), 106-111, 2015 | 36 | 2015 |
| AAV1. NT-3 gene therapy for X-linked Charcot–Marie–Tooth neuropathy type 1 B Ozes, M Myers, K Moss, J Mckinney, A Ridgley, L Chen, S Bai, ... Gene therapy 29 (3-4), 127-137, 2022 | 29 | 2022 |
| SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways N Zohrap, Ö Saatci, B Ozes, I Coban, HM Atay, E Battaloglu, Ö Şahin, ... Oncotarget 9 (31), 21876, 2018 | 28 | 2018 |
| AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in GarsP278KY/+ mice B Ozes, K Moss, M Myers, A Ridgley, L Chen, D Murrey, Z Sahenk Brain communications 3 (4), fcab252, 2021 | 18 | 2021 |
| High frequency of GJA12/GJC2 mutations in Turkish patients with Pelizaeus–Merzbacher disease B Bilir, Z Yapici, C Yalcinkaya, I Baris, CMB Carvalho, M Bartnik, B Ozes, ... Clinical genetics 83 (1), 66-72, 2013 | 12 | 2013 |
| Systemic delivery of AAVrh74. tMCK. hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1 Z Sahenk, B Ozes, D Murrey, M Myers, K Moss, ME Yalvac, A Ridgley, ... Molecular Therapy-Methods & Clinical Development 22, 401-414, 2021 | 11 | 2021 |
| AAV1. NT-3 gene therapy prevents age-related sarcopenia B Ozes, L Tong, M Myers, K Moss, A Ridgley, Z Sahenk Aging (Albany NY) 15 (5), 1306, 2023 | 4 | 2023 |
| Clinical and genetic aspects of hereditary spastic paraplegia in patients from Turkey NH Akçakaya, BÖ Ak, MA Gonzalez, S Züchner, E Battaloğlu, Y Parman Neurologia i neurochirurgia polska 54 (2), 176-184, 2020 | 2 | 2020 |
| TDP-43 Proteinopatileri: Nörodejeneratif konformasyon bozukluğu hastalıklarında yeni bir oyuncu S Lahut, B Özeş, S Ağar, AN Başak Turkish Journal of Neurology 18, 1-10, 2012 | 2 | 2012 |
| AAV1. NT‐3 gene therapy in the SOD1KO mouse model of accelerated sarcopenia L Tong, B Ozes, K Moss, M Myers, A Ridgley, Z Sahenk Journal of Cachexia, Sarcopenia and Muscle, 2023 | 1 | 2023 |
| NT-3 gene transfer therapy attenuates muscle pathology in the GarsP278KY/+ mice model of CMT2D B Ozes, K Moss, M Myers, A Ridgley, L Chen, D Murrey, Z Sahenk JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 26 (3), 369-370, 2021 | | 2021 |
| AAV1. NT-3 Gene Therapy Improves Motor Function in Accelerated Aging Model SOD1KO Mice B Ozes, M Myers, K Moss, A Ridgley, L Chen, D Murrey, Z Sahenk MOLECULAR THERAPY 29 (4), 286-286, 2021 | | 2021 |
| AAV1. NT-3 gene therapy improves phenotype in GarsNmf249/+ mice, a Charcot-Marie-Tooth axonal type 2D (CMT2D) model B Ozes, M Myers, K Moss, A Ridgley, L Chen, D Murrey, R Burgess, ... JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 25 (4), 505-505, 2020 | | 2020 |
| AAV. CAPN3 gene therapy for Limb-girdle muscular dystrophy type 2A (LGMD2A): Phenotypic improvements in the calpain3 (CAPN3)-null mouse B Ozes, D Murrey, M Myers, L Chen, K Moss, A Ridgley, C Wier, Z Sahenk NEUROMUSCULAR DISORDERS 30, S66-S66, 2020 | | 2020 |
| Biopotency and Biodistribution/Toxicology Studies Following Systemic Gene Therapy with AAVrh74. tMCK. hCAPN3 in the Mouse Model for LGMD2A DA Murrey, B Ozes, L Chen, M Myers, K Moss, A Ridgley, Z Sahenk MOLECULAR THERAPY 28 (4), 490-490, 2020 | | 2020 |
Esra BattaloğluProfessor of Molecular Genetics, Bogazici Universityboun.edu.tr üzerinde doğrulanmış e-posta adresine sahip
